Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact

Laurie Glimcher

Laurie Glimcher is a world-class immunologist who discovered the master transcription factors that direct immune cells to commit and activate. She has also discovered a key anabolic bone pathway and become an expert on ER stress and lipoprotein production. Most recently, Glimcher discovered a critical signaling pathway in both tumor cells and host immune responses. All the while, she’s acted as an academic leader, at Harvard School of Public Health and as dean of Weill Cornell Medical School, and she is about to take the reins of the Dana-Farber Cancer Institute as President and CEO.

Published July 1, 2016, by Ushma S. Neill

Conversations with Giants in Medicine

Related articles

A conversation with Laurie Glimcher
Ushma S. Neill
Ushma S. Neill
Published July 1, 2016
Citation Information: J Clin Invest. 2016;126(7):2392-2393. https://doi.org/10.1172/JCI88964.
View: Text | PDF
Conversations with Giants in Medicine

A conversation with Laurie Glimcher

  • Text
  • PDF
Abstract

Authors

Ushma S. Neill

×
Advertisement

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts